Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.

Abstract

Drug interactions due to efflux transport inhibition at the blood-brain barrier (BBB) have been receiving increasing scrutiny because of the theoretical possibility of adverse central nervous system (CNS) effects identified in preclinical studies. In this review, evidence from pharmacokinetic, pharmacodynamic, imaging, pharmacogenetic, and pharmacovigilance… (More)
DOI: 10.1038/clpt.2013.34

Topics

Cite this paper

@article{Kalvass2013WhyCM, title={Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.}, author={J. Cory Kalvass and Jim Polli and David L. Bourdet and B. Feng and Shih-Ming Huang and X. Liu and Quentin R. Smith and L K Zhang and Maciej J. Zamek-Gliszczynski}, journal={Clinical pharmacology and therapeutics}, year={2013}, volume={94 1}, pages={80-94} }